Mammalian Polyclonal IgG Antibody Market Analysis 2014-2018 & 2025 By Type (Mouse, Rabbit), Product (Cardiac, Metabolic), Application, End Use, & Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 16, 2018--The “Mammalian Polyclonal IgG Antibody Market Size, Share & Trends Analysis Report By Type (Mouse, Rabbit), By Product (Cardiac, Metabolic), By Application, By End Use, By Region, And Segment Forecasts, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.
The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.21 billion by 2025 expanding at a CAGR of 5.1%.
Advantages over other forms of antibodies, increasing global R&D investments, and rising adoption of novel diagnostic procedures are factors driving the market. Global rise in chronic and infectious diseases also play a key role in propelling the market growth.
Polyclonal antibodies are the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these does not require skilled professionals and large batches can be produced as per client requirements. A polyclonal antibody can recognize multiple antigens on one epitope and therefore can be utilized in the study of various diseases ranging from cancer to metabolic diseases. Denatured proteins are often detected with the use of polyclonal antibodies.
Thus, increasing use of these products in the treatment of several chronic diseases is also anticipated to fuel growth in the near future. Rising investments by major pharma companies, such as Novartis and Roche, for the development of therapeutic antibodies and novel diagnostic techniques and for QC purposes are also driving the market growth.
For instance, R&D investments by top 10 biotech companies increased from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, accounting for a 13% increase.
Further key findings from the study suggest:Large amount of polysera obtained from goats and predominant use of these animals as hosts has contributed to its large market share in 2017 Metabolic biomarkers are expected to hold the largest market share during the forecast period due to growing prevalence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer ELISA tests provide accurate diagnosis of disease, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial and viral infections, than other antibody-based assays contributing to its high market share Availability of technologically advanced equipment and presence of major market players has attributed to the North American region garnering large market share Asia Pacific is anticipated to gain significant market share in near future due to rising R&D investment and presence of target population Few key companies in the global mammalian polyclonal IgG antibody market include Abcam PLC; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific; Merck KgaA; Cell Signalling Technologies, Inc.; and Hoffmann-La Roche Ltd.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Mammalian Polyclonal IgG Antibody Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market Driver Analysis 126.96.36.199 Advantages Over Monoclonal Antibodies 188.8.131.52 Rising R&D investments 184.108.40.206 Increasing Adoption of Novel Diagnostic Procedures 3.1.2 Market Restraint Analysis 220.127.116.11 Stringent Regulatory Policies 3.1.3 Key Opportunities Prioritized 18.104.22.168 Key Opportunities Prioritized, by type 22.214.171.124 Key Opportunities Prioritized, by product 126.96.36.199 Key Opportunities Prioritized, by Application 188.8.131.52 Key Opportunities Prioritized, by End Use 3.1.4 Mammalian IgG Polyclonal Antibody - SWOT Analysis, By Factor (Political & Legal, Economic and Technological) 3.1.5 Industry Analysis - Porter’s 3.1.6 Mammalian IgG Polyclonal Antibody Market: Company Market Position Analysis, 2017
Chapter 4 Mammalian Polyclonal IgG Antibody Market: Type Analysis 4.1 Type Business Analysis 4.2 Mammalian IgG Polyclonal Antibody Market: Type Movement Analysis 4.2.1 Goat 4.2.2 Rabbit 4.2.3 Horse 4.2.4 Mouse 4.2.5 Others
Chapter 5 Mammalian Polyclonal IgG Antibody Market: Product Analysis 5.1 Product Business Analysis 5.2 Cardiac Biomarkers 5.3 Metabolic Biomarkers 5.4 Renal Biomarkers 5.5 Others
Chapter 6 Mammalian Polyclonal IgG Antibody Market: Application Analysis 6.1 Application Business Analysis 6.1.1 ELISA 6.1.2 Immunoturbidimetry 6.1.3 Immunoelectrophoresis 6.1.4 Antibody Identification 6.1.5 Immunohistochemistry 6.1.6 Immunocytochemistry 6.1.7 Western Blotting
Chapter 7 Mammalian Polyclonal IgG Antibody Market: End Use Analysis 7.1 End Use Business Analysis 7.2 Hospitals 7.3 Diagnostic Centers 7.4 Academic and Research Centers
Chapter 8 Mammalian Polyclonal IgG Antibody Market: Regional Estimates & Trend Analysis, by Type, Product, Application, End-Use
Chapter 9 Competitive LandscapeAbcam plc. Bio-Rad Laboratories Thermo Fisher Scientific Merck KGaA Cell Signaling Technologies Hoffmann-La Roche Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/ct6q25/mammalian?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181116005314/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Biotechnology,Immune Disorders Drugs,Biopharmaceuticals
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/16/2018 10:29 AM/DISC: 11/16/2018 10:28 AM